Anthem Bioscienc

Why is Anthem Biosciences Ltd falling/rising?

As of 30-Jul, Anthem Biosciences Ltd's stock price is at 783.50, down 0.77% due to reduced trading activity and investor interest. Despite this short-term decline, the company maintains strong long-term fundamentals, including a 19.93% average ROE and healthy profit growth.

As of 30-Jul, Anthem Biosciences Ltd's stock price is currently at 783.50, reflecting a decrease of 6.1 points or 0.77%. This decline can be attributed to its performance today, where it underperformed the sector by 0.46%. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 76.92% compared to the 5-day average, indicating reduced trading activity and interest in the stock.<BR><BR>Despite the current decline, it is important to note that Anthem Biosciences has shown strong long-term fundamental strength, with an average Return on Equity (ROE) of 19.93% and healthy growth in operating profit at an annual rate of 44.32%. Furthermore, the company is net-debt free, which typically supports a positive long-term outlook. However, the immediate price movement reflects current market conditions and investor sentiment rather than the company's overall financial health.

Which are the latest news on Anthem Bioscienc?

Are Anthem Biosciences Ltd latest results good or bad?

Anthem Biosciences Ltd's latest results are concerning, showing a 31.54% sequential revenue decline to ₹418.22 crores and a 36.79% drop in net profit to ₹119.94 crores, indicating significant operational challenges and raising questions about the company's growth sustainability.

Anthem Biosciences Ltd's latest results are concerning, reflecting a significant downturn in performance. In the quarter ending June 2026, the company experienced a sharp revenue decline of 31.54% sequentially, with net sales dropping to ₹418.22 crores from ₹610.94 crores in the previous quarter. This marks the lowest quarterly revenue the company has seen in recent times and represents a 22.58% decline year-on-year.<BR><BR>The operating profit also took a hit, decreasing by 43.64% to ₹150.57 crores, leading to a compression in operating margins from 43.74% to 36.0%. Additionally, net profit fell by 36.79% quarter-on-quarter to ₹119.94 crores, indicating a challenging operational environment.<BR><BR>Overall, the results suggest that Anthem Biosciences is facing significant operational challenges, raising questions about its growth sustainability and the factors contributing to this sharp contraction. The company’s performance in this quarter is classified as a setback, contrasting sharply with its previous strong showing.

Should I buy, sell or hold Anthem Biosciences Ltd?

When is the next results date for Anthem Biosciences Ltd?

Anthem Biosciences Ltd will announce its results on July 21, 2026.

Anthem Biosciences Ltd is scheduled to declare its results on July 21, 2026.

What does Anthem Bioscienc do?

Anthem Biosciences Ltd is a Mid Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 611 Cr and a net profit of 190 Cr for the quarter ending March 2026. It has a market cap of INR 43,400 Cr and key metrics include a P/E ratio of 71.00 and a return on equity of 21.62%.

Overview:<BR>Anthem Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Anthem Biosciences Ltd was originally incorporated as "Anthem Biosciences Private Limited" in 2006. The company transitioned from a Private to a Public Company and changed its name to "Anthem Biosciences Limited," with the conversion certified on December 10, 2024. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 611 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 190 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 43,400 Cr (Mid Cap) <BR><BR>Key Metrics:<BR>P/E: 71.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: 21.62% <BR>Price to Book: 13.71 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Anthem Bioscienc?

As of 10th June, Anthem Biosciences Ltd has a market capitalization of 43,400.00 Cr and reported net sales of 2,124.33 Cr and net profit of 591.80 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Anthem Biosciences Ltd has a market capitalization of 43,400.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,124.33 Cr, while the sum of Net Profit for the same period is 591.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 2,409.86 Cr, and Total Assets are valued at 2,789.64 Cr.

Who are the peers of the Anthem Bioscienc?

Anthem Bioscienc's peers include Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Ipca Labs, Gland Pharma, Ajanta Pharma, and Glaxosmi. Pharma. Anthem Bioscienc shows excellent growth and capital structure, while its peers vary in management risk and return performance.

Peers: The peers of Anthem Bioscienc are Laurus Labs, Biocon, Alkem Lab, Glenmark Pharma, Abbott India, Ipca Labs, Gland Pharma, Ajanta Pharma, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India, Ajanta Pharma, and Glaxosmi. Pharma, while Good management risk is found at Laurus Labs, Alkem Lab, Glenmark Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, and J B Chemicals &. Average management risk is present at Biocon. In terms of Growth, Anthem Bioscienc stands out with Excellent growth, while Good growth is noted at Glenmark Pharma and the rest have Below Average growth. For Capital Structure, Excellent ratings are given to Alkem Lab, Abbott India, Anthem Bioscienc, Ajanta Pharma, Glaxosmi. Pharma, and J B Chemicals &, while Average is noted at Laurus Labs and Good at Glenmark Pharma, Ipca Labs, and Gland Pharma.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.26%, while Glaxosmi. Pharma has the lowest at -36.12%. Anthem Bioscienc does not have a 1-year return available for comparison. Additionally, Abbott India and Glaxosmi. Pharma have negative six-month returns.

Has Anthem Biosciences Ltd declared dividend?

Yes, Anthem Biosciences Ltd has declared a 100% dividend, with an ex-date of June 25, 2026. However, the company has shown no price or dividend returns over the longer periods, indicating a need for performance improvement.

Anthem Biosciences Ltd has declared a 100% dividend.<BR><BR>Dividend Details:<BR>Percentage announced: 100%<BR>Ex-date: 25 Jun 26<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, Anthem Biosciences Ltd achieved a price return of 13.0%, a dividend return of 0.29%, resulting in a total return of 13.29%.<BR><BR>Over the past 6 months, the company recorded a price return of 21.11%, a dividend return of 0.32%, leading to a total return of 21.43%.<BR><BR>For the 1-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 2-year period, the company saw no price return or dividend return, culminating in a total return of 0.0%.<BR><BR>Over the last 3 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Finally, in the 5-year period, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, while Anthem Biosciences Ltd has declared a significant dividend, the total returns over the longer periods indicate a lack of growth in price and dividends, suggesting a need for improvement in performance.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.